Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Studying the amount of fibrinogen in the blood plasma of dogs is essential in determining the severity of the inflammatory process. In this regard, the aim of this work was to establish the level of fibrinogen in animals with the purulent-inflammatory process. The studies were performed by spectrophotometric method according to the generally accepted method. During the studies, the content of fibrinogen in the blood plasma of clinically healthy dogs was determined before medical care and during the wound process on the 3rd, 7th, 10th and 14th days of treatment. The results of the study on dogs with purulent skin wounds revel that the amount of fibrinogen before treatment was 2 times higher (p<0.001) compared with clinically healthy animals. On the 3rd day of the study, the content of fibrinogen in blood plasma in the animals of experimental group 1 and experimental group 2 was, respectively, 1.6 (p<0.001) and 1.5 (p<0.001) times higher than in the clinically healthy animals; the amount of fibrinogen was 1.7 times (p<0.001) higher in the control group of animals than in the clinically healthy dogs. On the 7th day of treatment, the level of fibrinogen in animals of the experimental group 1 was 1.2 times (p<0,01) higher than in clinically healthy dogs, while in the experimental group 2 its content was 1.1 times (p<0.05) higher. In contrast, it was 1.4 times (p<0.001) higher the control group dogs than in clinically healthy animals. Studies have shown that the administration of succinic acid and intravenous 1.5% solution of reamberin, a drug based on succinic acid, restores the level of fibrinogen in the plasma of dogs with purulent wounds on the 10th day of the wound process, compared with intravenous introduction of 5% glucose solution. The best therapeutic effect was obtained in the group of animals treated with 1.5% solution of reamberin
Studying the amount of fibrinogen in the blood plasma of dogs is essential in determining the severity of the inflammatory process. In this regard, the aim of this work was to establish the level of fibrinogen in animals with the purulent-inflammatory process. The studies were performed by spectrophotometric method according to the generally accepted method. During the studies, the content of fibrinogen in the blood plasma of clinically healthy dogs was determined before medical care and during the wound process on the 3rd, 7th, 10th and 14th days of treatment. The results of the study on dogs with purulent skin wounds revel that the amount of fibrinogen before treatment was 2 times higher (p<0.001) compared with clinically healthy animals. On the 3rd day of the study, the content of fibrinogen in blood plasma in the animals of experimental group 1 and experimental group 2 was, respectively, 1.6 (p<0.001) and 1.5 (p<0.001) times higher than in the clinically healthy animals; the amount of fibrinogen was 1.7 times (p<0.001) higher in the control group of animals than in the clinically healthy dogs. On the 7th day of treatment, the level of fibrinogen in animals of the experimental group 1 was 1.2 times (p<0,01) higher than in clinically healthy dogs, while in the experimental group 2 its content was 1.1 times (p<0.05) higher. In contrast, it was 1.4 times (p<0.001) higher the control group dogs than in clinically healthy animals. Studies have shown that the administration of succinic acid and intravenous 1.5% solution of reamberin, a drug based on succinic acid, restores the level of fibrinogen in the plasma of dogs with purulent wounds on the 10th day of the wound process, compared with intravenous introduction of 5% glucose solution. The best therapeutic effect was obtained in the group of animals treated with 1.5% solution of reamberin
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.